Responses
Viewpoint
Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y12 receptor antagonists?
Compose a Response to This Article
Other responses
Jump to comment:
- Published on: 23 November 2015
- Published on: 23 November 2015What is the best dose of aspirin in association with P2Y12 antagonists?Show More
In their Viewpoint article, Warner et al hypothesized that the administration of aspirin to patients who are treated with potent antagonists of the platelet P2Y12 receptors might increase cardiovascular risk.1 The authors' hypothesis is based on the observation that P2Y12 antagonists inhibit the platelet production of thromboxane A2 (TxA2) (which would render the use of aspirin superfluous), and on the consideration tha...
Conflict of Interest:
None declared.